Can extra rituximab keep vasculitis at bay?
NCT ID NCT02433522
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This study looked at whether giving rituximab for a longer period (46 months) is better than the usual 18-month treatment for preventing relapses of ANCA-associated vasculitis, a rare autoimmune disease. 97 patients who were already in remission after initial rituximab therapy were randomly assigned to receive either rituximab or a placebo every 6 months. The goal was to see if extended treatment keeps the disease from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIDES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hopital cochin
Paris, 75014, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab
What this could lead to
If successful, this could show that extending rituximab treatment for several years helps prevent disease relapses in people with ANCA-associated vasculitis.
What could go wrong
This is a small, completed Phase 3 trial with only 97 participants, so results may not apply to everyone. Extended immune suppression also raises infection risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.